MetaVia Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MTVA Nasdaq 2836 www.metaviatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MetaVia Inc.

MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Aug 6th, 2026 2:05 pm
Sector Update: Healthcare Stocks Softer Late Afternoon - Jul 9th, 2026 1:49 pm
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity - Jul 9th, 2026 6:31 am
OTC Markets Life Sciences Investor Forum: MetaVia CEO HH Kim and CFO Marshall Woodworth with Zacks SCR's David Bautz - Jun 30th, 2026 8:42 am
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing - Jun 26th, 2026 6:35 am
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th - Jun 23rd, 2026 6:35 am
MTVA: Vanoglipel and DA-1726 Data Presented at ADA 2026 Scientific Sessions - Jun 17th, 2026 7:18 am
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum - Jun 17th, 2026 6:31 am
Presenting on Emerging Growth Conference 93 Day 2 on June 11; Register to live stream - Jun 10th, 2026 5:00 am
BioStem Technologies Announces Appointment of Three New Members to its Board of Directors - Jun 9th, 2026 5:00 am
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential - Jun 8th, 2026 6:31 am
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference - Jun 4th, 2026 6:31 am
MTVA: No Evidence for Changes in Cardiovascular Parameters in Phase 1 Trial of DA-1726 - May 28th, 2026 4:54 am
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH - May 27th, 2026 6:31 am
MTVA: Multiple Upcoming Presentations to Highlight DA-1726 and Vanoglipel - May 21st, 2026 7:06 am
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH - May 20th, 2026 6:00 am
Sector Update: Healthcare Stocks Gain Late Afternoon - May 19th, 2026 1:55 pm
Sector Update: Healthcare Stocks Rise Tuesday Afternoon - May 19th, 2026 12:02 pm
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions - May 18th, 2026 6:31 am
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update - May 14th, 2026 2:05 pm